BRNS vs ADCT

For growth investors, ADC Therapeutics S.

A. (ADCT) is the stronger pick with 14. 9% revenue growth year-over-year, versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). Analysts rate ADC Therapeutics S. A. (ADCT) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, ADC Therapeutics S.

A. (ADCT) delivered a total return of -84. 1%, compared to -95. 0% for Barinthus Biotherapeutics plc (BRNS). Over 10 years, the gap is even starker: ADCT returned -87. 3% versus BRNS's -95. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Barinthus Biotherapeutics plc (BRNS) is the lower-risk stock at 1.

28β versus ADC Therapeutics S. A. 's 1. 89β — meaning ADCT is approximately 47% more volatile than BRNS relative to the S&P 500.

By revenue growth (latest reported year), ADC Therapeutics S.

A. (ADCT) is pulling ahead at 14. 9% versus -100. 0% for Barinthus Biotherapeutics plc (BRNS). On earnings-per-share growth, the picture is similar: ADC Therapeutics S. A. grew EPS 30. 9% year-over-year, compared to -5. 8% for Barinthus Biotherapeutics plc. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Barinthus Biotherapeutics plc (BRNS) is the more profitable company, earning 0.

0% net margin versus -175. 3% for ADC Therapeutics S. A. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRNS leads at 0. 0% versus -133. 2% for ADCT. At the gross margin level — before operating expenses — ADCT leads at 90. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Barinthus Biotherapeutics plc (BRNS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

28)). ADC Therapeutics S. A. (ADCT) carries a higher beta of 1. 89 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BRNS: -95. 2%, ADCT: -87. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.